# Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer

Source: https://onco.cc/trials/nct05498155/  
OnCo record `nct05498155` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Olaparib and Durvalumab in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.

## Summary

Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer is a phase 2 interventional study registered as NCT05498155 by AstraZeneca, with 50 participants enrolled, started 2022-11-07 and due to reach its primary completion in 2024-11-20. Interventions recorded: Neoadjuvant Olaparib monotherapy group and Neoadjuvant combination therapy with olaparib plus durvalumab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05498155
- Phase: 2
- Setting: A Phase II, Multicentre, Open-Label Study to Assess the Efficacy and Safety of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination as Neoadjuvant Therapy in Patients With BRCA Mutations and Early Stage HER2-Negative Breast Cancer
- Sponsor: AstraZeneca
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT05498155: https://clinicaltrials.gov/study/NCT05498155

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/), [Olaparib](https://onco.cc/drugs/olaparib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct05498155.json